Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a note issued to investors on Friday,RTT News reports. They presently have a $21.00 target price on the stock. Wedbush’s price target points to a potential upside of 37.80% from the stock’s current price.

IMNM has been the topic of several other research reports. The Goldman Sachs Group started coverage on Immunome in a research report on Monday, September 22nd. They set a “buy” rating and a $26.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and set a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Wednesday, October 8th. Evercore ISI began coverage on shares of Immunome in a research report on Friday, August 22nd. They set an “outperform” rating and a $18.00 price target for the company. Finally, Craig Hallum assumed coverage on shares of Immunome in a report on Friday, September 5th. They issued a “buy” rating and a $26.00 price target on the stock. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Immunome has an average rating of “Moderate Buy” and an average target price of $23.20.

Immunome Stock Down 1.7%

Shares of IMNM stock traded down $0.26 on Friday, hitting $15.24. The stock had a trading volume of 1,665,412 shares, compared to its average volume of 1,235,020. Immunome has a one year low of $5.15 and a one year high of $17.87. The business has a 50 day moving average price of $12.83 and a 200 day moving average price of $10.48. The company has a market cap of $1.33 billion, a PE ratio of -5.17 and a beta of 1.96.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 77.37%. Equities research analysts expect that Immunome will post -2.21 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of IMNM. MetLife Investment Management LLC boosted its position in Immunome by 19.1% in the first quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock valued at $285,000 after buying an additional 6,792 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Immunome by 55.0% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock valued at $5,216,000 after acquiring an additional 275,000 shares during the period. Exome Asset Management LLC purchased a new stake in shares of Immunome in the 1st quarter valued at $1,776,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Immunome by 34.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 614,387 shares of the company’s stock valued at $4,135,000 after acquiring an additional 157,135 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Immunome by 3.2% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 53,187 shares of the company’s stock worth $470,000 after acquiring an additional 1,643 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.